Efficacy and Safety Study of AeroVanc for the Treatment of Persistent MRSA Lung Infection in Cystic Fibrosis Patients

This study is currently recruiting participants. (see Contacts and Locations)
Verified June 2014 by Savara Inc.
Sponsor:
Collaborators:
Synteract, Inc.
Cystic Fibrosis Foundation
Information provided by (Responsible Party):
Savara Inc.
ClinicalTrials.gov Identifier:
NCT01746095
First received: December 6, 2012
Last updated: June 23, 2014
Last verified: June 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: November 2014
  Estimated Primary Completion Date: November 2014 (Final data collection date for primary outcome measure)